Quick Links

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 1 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hours.

This activity is supported by an educational grant from ­­­­­­­­­­­­­­Portola Pharmaceuticals

2 Clarke Drive
Suite 110
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2020
Physicians’ Education Resource ®, LLC.
All rights reserved.

Direct Acting Oral Anticoagulants (DOACs) and Reversal Agents: Updates for the Hospitalist

Direct Acting Oral Anticoagulants (DOACs) and Reversal Agents: Updates for the Hospitalist

In order to request this CME/CE activity for your center, please contact Samantha Zelasko at or call (609)325-4668.

January 2018 – November 2018


Anticoagulant therapy plays a vital role in treating patients and preventing serious and potentially fatal complications resulting from venous thromboembolism and atrial fibrillation.  Direct acting oral anticoagulants (DOACs) offer several advantages over traditional vitamin K antagonist therapy with a more predictable anticoagulant response, fewer drug interactions, and significantly less risk of hemorrhagic stroke when compared to warfarin.  However, in the past, the absence of a clear, effective reversal strategy was a concern with the new oral anticoagulant agents.

This Best Practice® program will review the efficacy and safety of new and emerging anticoagulation reversal agents as well as recommended strategies for DOAC reversal.  Incorporation of individual patient-specific factors will be addressed with patient cases to exemplify implementation of reversal strategies.   Throughout the program, we hope that you will take advantage of all the opportunities to interact with our faculty to ensure that your most pressing clinical questions are answered

Target Audience: This program is directed towards hospitalists, residents, surgeons, anesthesiologists and other hospital-based providers who care for patients requiring DOAC and/or reversal agents.

Learning Objectives:

  • REVIEW the evidence supporting safety and efficacy of DOAC therapy for approved clinical indications
  • EXAMINE the mechanism of action, efficacy and real-world data and clinical indications of DOAC reversal agents.
  • EVALUATE currently recommended strategies for DOAC reversal and risk of adverse effects.
  • IMPLEMENT anticoagulation reversal treatment regimens for DOACs accounting for individual patient-specific factors

Acknowledgment of Commercial Support

This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Portola Pharmaceuticals Inc.
Calendar of Events
Filter By